Showing posts tagged with "clinical-forensic-and-doping-testing"
Introduction The screening of patient urine samples for basic drugs is typically performed following a lengthy sample preparation methodology that requires a time consuming dry down step. A novel elut...
This procedure utilizes the ISOLUTE® HCX 130 mg/10 mL configuration, optimized for the extraction of basic drugs from 5 mL of urine, and ideal for applications with GC-MS end points. Literature number...
For research use only. NOT for use in diagnostic procedures.
Introduction Tobacco-specific nitrosamines, TSNAs, are carcinogens found in tobacco products, including e-cigarettes and smokeless tobacco. NNN (n-nitrosonornicotine), NNK (4-(methylnitrosamino)-1-(3-...
Abstract Extraction of drugs of abuse panels from whole blood samples can be challenging, especially when analyzing a broad panel of analytes from different classes. This white paper studies the analy...
Abstract Extraction of drugs of abuse panels from whole blood samples can be challenging, especially when analyzing a broad panel of analytes from different classes. This white paper studies the analy...
Abstract Extraction of drugs of abuse panels from whole blood samples can be challenging, especially when analyzing a broad panel of analytes from different classes. This white paper studies the analy...
This application note describes the extraction of a range of SPICE drugs and metabolites in urine which are typically screened in forensic toxicology panels using ISOLUTE® SLE+ in a 96-well plate form...
Introduction The detection of per- and polyfluoroalkyl substances (PFAS) within our air, water, and soil has confirmed their place as persistent pollutants that pose significant health risks upon huma...
Introduction This application note describes a solid phase extraction (SPE) protocol for the extraction of teicoplanin from plasma prior to HPLC-DAD analysis. Teicoplanin (Figure 1) is a glycopeptide ...